Table 3.
Clinical efficacy and AEs of SLIT.
| 1 year group | 2 years group | 3 years group | |
|---|---|---|---|
| Baseline score | |||
| TNSS | 6.02 ± 2.56 | 5.93 ± 2.80 | 5.65 ± 2.28 |
| RMS | 0.92 ± 0.87 | 0.85 ± 0.88 | 1.01 ± 0.88 |
| SMS | 6.95 ± 2.82 | 6.78 ± 2.96 | 6.66 ± 2.47 |
| The end of SLIT | |||
| TNSS | 3.01 ± 2.04∗ | 2.39 ± 2.22∗# | 1.93 ± 1.65∗# |
| RMS | 0.21 ± 0.41∗ | 0.16 ± 0.37∗# | 0.06 ± 0.25∗# |
| SMS | 3.21 ± 2.12∗ | 2.55 ± 2.38∗# | 2.01 ± 1.75∗# |
| 2 years after cessation of SLIT | |||
| TNSS | 5.26 ± 2.18$ | 4.21 ± 1.95∗#$ | 1.88 ± 1.72∗#& |
| RMS | 0.87 ± 0.76$ | 0.57 ± 0.32∗#$ | 0.05 ± 0.18∗#& |
| SMS | 6.48 ± 2.95$ | 4.69 ± 2.21∗#$ | 2.19 ± 1.58∗#& |
| AEs | |||
| Allergic symptom | 5 | 3 | 6 |
| Local irritation symptom | 3 | 3 | 4 |
| Gastrointestinal symptom | 2 | 1 | 0 |
| Other minor symptom | 2 | 1 | 1 |
SLIT, sublingual immunotherapy; TNSS, total nasal symptom score; RMS, Rescue medication score; SMS, symptom medication score; AEs, adverse events. ∗ Compared with baseline score, P < 0.05. # Compared with 1 year group, P < 0.05. $ Compared with the end of SLIT, P < 0.05. & Compared with 2 years group, P < 0.05